Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 23;1(1):R1-R11.
doi: 10.1530/VB-18-0004. eCollection 2019.

GPCR transactivation signalling in vascular smooth muscle cells: role of NADPH oxidases and reactive oxygen species

Raafat Mohamed  1   2 , Reearna Janke  1 , Wanru Guo  1 , Yingnan Cao  3 , Ying Zhou  1 , Wenhua Zheng  4 , Hossein Babaahmadi-Rezaei  5 , Suowen Xu  6 , Danielle Kamato  1   3 , Peter J Little  1   3
Affiliations
Review

GPCR transactivation signalling in vascular smooth muscle cells: role of NADPH oxidases and reactive oxygen species

Raafat Mohamed et al. Vasc Biol. .

Abstract

The discovery and extension of G-protein-coupled receptor (GPCR) transactivation-dependent signalling has enormously broadened the GPCR signalling paradigm. GPCRs can transactivate protein tyrosine kinase receptors (PTKRs) and serine/threonine kinase receptors (S/TKRs), notably the epidermal growth factor receptor (EGFR) and transforming growth factor-β type 1 receptor (TGFBR1), respectively. Initial comprehensive mechanistic studies suggest that these two transactivation pathways are distinct. Currently, there is a focus on GPCR inhibitors as drug targets, and they have proven to be efficacious in vascular diseases. With the broadening of GPCR transactivation signalling, it is therefore important from a therapeutic perspective to find a common transactivation pathway of EGFR and TGFBR1 that can be targeted to inhibit complex pathologies activated by the combined action of these receptors. Reactive oxygen species (ROS) are highly reactive molecules and they act as second messengers, thus modulating cellular signal transduction pathways. ROS are involved in different mechanisms of GPCR transactivation of EGFR. However, the role of ROS in GPCR transactivation of TGFBR1 has not yet been studied. In this review, we will discuss the involvement of ROS in GPCR transactivation-dependent signalling.

Keywords: G protein; GPCR; TGF-beta; epidermal growth factor; transactivation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review. Professor P Little is a Senior Editor of Vascular Biology. Dr D Kamato is an Early Career Researcher on the Editorial Board of Vascular Biology. Professor Little and Dr Kamato were not involved in the review or editorial process for this paper, on which they are listed as authors.

Figures

Figure 1
Figure 1
Schematic representation of known and speculated roles of NADPH oxidase (Nox) and ROS in G-protein-coupled receptor (GPCR) transactivation of epidermal growth factor receptor (EGFR). GPCR transactivation of EGFR occurs via an increase in intracellular reactive oxygen species (ROS) which in turn (1) activate matrix metalloproteinase (MMP) that cleaves heparin-binding EGF-like growth factor (pro-HB-EGF) and release the EGF ligand leading to EGFR activation and subsequently phosphorylation of downstream intermediate extracellular signal-regulated kinase1/2 (ERK1/2). GPCR stimulation of ROS activates the EGFR (2) via Src-dependent pathway and (3) through inhibition of protein tyrosine phosphatases (PTPs).
Figure 2
Figure 2
Schematic representation of the mechanism of G-protein-coupled receptor (GPCR) transactivation of transforming growth factor-β type 1 receptor (TGFBR1). GPCR transactivation of TGFBR1 occurs via cytoskeletal rearrangement which activates Rho-associated protein kinase (RhoA/ROCK) signalling and cell-surface integrin. Activated integrin binds to and activates the large latent TGF-β complex (LLC), leading to the subsequent phosphorylation of the downstream intermediate Smad2 in the carboxy terminal.
See this image and copyright information in PMC

References

    1. Klabunde T, Hessler G. Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem 2002. 3 . ( 10.1002/1439-7633(20021004)3:10<928::AID-CBIC928>3.0.CO;2-5) - DOI - PubMed
    1. Mcneely PM, Naranjo AN, Robinson AS. Structure-function studies with G protein-coupled receptors as a paradigm for improving drug discovery and development of therapeutics. Biotechnology Journal 2012. 7 . ( 10.1002/biot.201200076) - DOI - PMC - PubMed
    1. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends in Pharmacological Sciences 2001. 22 . ( 10.1016/S0165-6147(00)01678-3) - DOI - PubMed
    1. Kamato D, Rostam MA, Bernard R, Piva TJ, Mantri N, Guidone D, Zheng W, Osman N, Little PJ. The expansion of GPCR transactivation-dependent signalling to include serine/threonine kinase receptors represents a new cell signalling frontier. Cellular and Molecular Life Sciences 2015. 72 . ( 10.1007/s00018-014-1775-0) - DOI - PMC - PubMed
    1. Lefkowitz RJ. Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends in Pharmacological Sciences 2004. 25 . ( 10.1016/j.tips.2004.06.006) - DOI - PubMed